| Literature DB >> 36245624 |
Jun Hanaoka1, Makoto Yoden2, Keigo Okamoto1, Ryosuke Kaku1, Yasuhiko Ohshio1.
Abstract
Background: Mediastinal lymph node (LN) dissection during lung resection is essential for accurate staging. Station 4L dissection is anatomically difficult. Therefore, care should be taken to avoid complications. We investigated the importance of mediastinal LN dissection in left upper lobe lung cancer and evaluated intraoperative videos to identify relevant steps during dissection.Entities:
Keywords: Lung cancer; lymph node (LN); lymph node dissection; recurrent laryngeal nerve palsy; video-assisted thoracoscopic surgery
Year: 2022 PMID: 36245624 PMCID: PMC9562556 DOI: 10.21037/jtd-22-537
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 3.005
Figure 1Surgical procedures for mediastinal lymph node dissection in left upper lobectomy. (A) Pleural incision along the lateral margin of the phrenic nerve (arrow head; from the superior pulmonary vein to the superior margin of the aortic arch) and identification along with en bloc resection of station 6 lymph nodes. (B) Peeling along the confirmed vagal nerve (white allow head) using scissors from the peripheral side to the bifurcation of the recurrent laryngeal nerve. (C) Peeling along the secured pulmonary artery to the ligamentum Botalli (white arrow), identification of the recurrent laryngeal nerve (black arrow head) running beside the ligamentum Botalli, and en bloc resection of station 5 lymph nodes. (D) Exposure of the tracheal wall (black arrow) by preventing damage to the recurrent laryngeal nerve and en bloc resection of lymph nodes from stations 4L to 10 along the left main bronchus.
Clinical characteristics of patients (n=139)
| Variables | Values |
|---|---|
| Age (years), mean | 69.39 (range, 47–90) |
| Smoking, n (%) | |
| Non-smoker | 36 (25.90) |
| Smoker | 103 (74.10) |
| Respiratory comorbidities, n (%) | |
| COPD | 49 (35.25) |
| BA | 6 (4.32) |
| IPF | 4 (2.88) |
| Others | 2 (1.44) |
| COPD stage (n=138), n (%) | |
| 0 | 89 (64.49) |
| 1 | 26 (18.84) |
| 2 | 22 (15.94) |
| 3 | 1 (0.72) |
| Respiratory history, n (%) | |
| Tuberculosis | 7 (5.04) |
| Pneumonia | 4 (2.88) |
| Others | 8 (5.76) |
| Clinical T factor, n (%) | |
| 1mi | 5 (3.60) |
| 1a | 19 (13.67) |
| 1b | 39 (28.06) |
| 1c | 30 (21.58) |
| 2a | 25 (17.99) |
| 2b | 8 (5.76) |
| 3 | 10 (7.19) |
| 4 | 3 (2.16) |
| Clinical N factor, n (%) | |
| 0 | 115 (82.73) |
| 1 | 11 (7.91) |
| 2 | 12 (8.63) |
| 3 | 1 (0.72) |
| Clinical stage, n (%) | |
| IA1 | 20 (14.39) |
| IA2 | 36 (25.90) |
| IA3 | 27 (19.42) |
| IB | 18 (12.95) |
| IIA | 6 (4.32) |
| IIB | 13 (9.35) |
| IIIA | 15 (10.79) |
| IIIB | 4 (2.88) |
| FDG-PET (n=123), n (%) | |
| Yes | 23 (18.70) |
| No | 100 (81.30) |
| Preoperative diagnosis, n (%) | |
| Yes | 61 (43.88) |
| No | 78 (56.12) |
| Mediastinoscopy, n (%) | |
| Yes | 69 (49.64) |
| No | 70 (50.36) |
| Bleeding (mL), mean | 209.7 |
| Pathological N factor, n (%) | |
| 0 | 108 (77.70) |
| 1 | 13 (9.35) |
| 2 | 18 (12.95) |
| Histology, n (%) | |
| Ad | 90 (64.75) |
| Sq | 32 (23.02) |
| Others | 17 (12.23) |
| Recurrence, n (%) | |
| Yes | 32 (23.02) |
| No | 107 (76.98) |
| Prognosis, n (%) | |
| Dead | 26 (18.71) |
| Alive | 113 (81.29) |
COPD, chronic obstructive pulmonary disease; BA, bronchial asthma; IPF, idiopathic pulmonary fibrosis; FDG-PET, fluorodeoxyglucose-positron emission tomography; Ad, adenocarcinoma; Sq, squamous cell carcinoma.
Figure 2Kaplan-Meier curves of (A) OS and (B) DFS according to pathological N factor. 5-year, 5-year survival; pN, pathological N; OS, overall survival; DFS, disease-free survival.
Univariate and multivariate analyses for the association between various risk factors and clinicopathological characteristics among patients with left upper lobe lung cancer (n=139)
| Variables | N | Univariate analysis | Multivariate analysis | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OS | DFS | OS | DFS | |||||||||||||
| P value | HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | |||||
| Age | ||||||||||||||||
| ≥70 years | 69 | 0.048 | 2.228 | 1.005–4.941 | 0.630 | 1.186 | 0.592–2.378 | 0.048 | 2.384 | 1.008–5.640 | ||||||
| <70 years | 70 | |||||||||||||||
| Sex | ||||||||||||||||
| Male | 96 | 0.114 | 2.361 | 0.813–6.856 | 0.155 | 1.905 | 0.784–4.631 | |||||||||
| Female | 43 | |||||||||||||||
| Brinkman index | ||||||||||||||||
| ≥400 | 94 | 0.015 | 5.973 | 1.41–25.3 | 0.324 | 1.496 | 0.672–3.333 | 0.052 | 4.441 | 0.989–19.950 | ||||||
| <400 | 45 | |||||||||||||||
| Respiratory comorbidities | ||||||||||||||||
| Yes | 56 | 0.048 | 2.192 | 1.006–4.774 | 0.011 | 2.48 | 1.224–5.026 | 0.602 | 1.246 | 0.545–2.848 | 0.058 | 2.257 | 0.972–5.244 | |||
| No | 83 | |||||||||||||||
| COPD stage | ||||||||||||||||
| ≥2 | 23 | 0.073 | 1.469 | 0.965–2.237 | 0.060 | 1.458 | 0.983–2.163 | |||||||||
| <2 | 115 | |||||||||||||||
| Respiratory history | ||||||||||||||||
| Yes | 19 | 0.190 | 1.842 | 0.739–4.596 | 0.163 | 1.816 | 0.785–4.204 | |||||||||
| No | 120 | |||||||||||||||
| Clinical T factor | ||||||||||||||||
| ≥2 | 46 | 0.014 | 2.639 | 1.22–5.71 | 0.001 | 3.188 | 1.584–6.415 | 0.147 | 1.915 | 0.796–4.608 | 0.112 | 1.917 | 0.860–4.271 | |||
| <2 | 93 | |||||||||||||||
| Clinical N factor | ||||||||||||||||
| ≥2 | 13 | 0.131 | 2.277 | 0.783–6.62 | 0.0792 | 2.353 | 0.905–6.116 | |||||||||
| <2 | 126 | |||||||||||||||
| Clinical stage | ||||||||||||||||
| ≥III | 19 | 0.034 | 2.553 | 1.072–6.084 | 0.005 | 3.019 | 1.395–6.531 | 0.839 | 1.110 | 0.406–3.029 | 0.841 | 1.096 | 0.450–2.670 | |||
| <III | 120 | |||||||||||||||
| FDG-PET accumulation | ||||||||||||||||
| Yes | 23 | 0.215 | 1.77 | 0.717–4.369 | 0.136 | 1.871 | 0.822–4.261 | |||||||||
| No | 100 | |||||||||||||||
| Mediastinoscopy | ||||||||||||||||
| Yes | 69 | 0.241 | 1.63 | 0.720–3.69 | 0.907 | 0.959 | 0.477–1.931 | |||||||||
| No | 70 | |||||||||||||||
| Approach | ||||||||||||||||
| Open thoracotomy | 48 | 0.006 | 3.025 | 1.369–6.687 | <0.001 | 3.765 | 1.836–7.723 | 0.281 | 1.707 | 0.646–4.510 | 0.519 | 1.374 | 0.523–3.609 | |||
| VATS | 91 | |||||||||||||||
| Bleeding | ||||||||||||||||
| ≥200 mL | 35 | 0.002 | 3.308 | 1.526–7.169 | 0.018 | 2.347 | 1.155–4.769 | 0.278 | 1.696 | 0.653–4.406 | 0.167 | 1.854 | 0.772–4.450 | |||
| <200 mL | 104 | |||||||||||||||
| Operation duration | ||||||||||||||||
| ≥300 min | 82 | 0.155 | 1.877 | 0.788–4.467 | 0.292 | 0.689 | 0.345–1.378 | |||||||||
| <300 min | 57 | |||||||||||||||
| Pathological N factor | ||||||||||||||||
| ≥2 | 16 | 0.278 | 1.806 | 0.621–5.253 | 0.003 | 3.379 | 1.511–7.552 | 0.010 | 3.883 | 1.379–10.930 | ||||||
| <2 | 123 | |||||||||||||||
| Histology | ||||||||||||||||
| Ad | 87 | 0.054 | 1.28 | 0.995–1.645 | 0.015 | 1.319 | 1.054–1.651 | 0.890 | 0.937 | 0.367–2.395 | 0.466 | 1.107 | 0.842–1.455 | |||
| Non-Ad | 52 | |||||||||||||||
| Adjuvant chemotherapy | ||||||||||||||||
| Yes | 45 | 0.954 | 1.024 | 0.456–2.30 | 0.015 | 2.363 | 1.181–4.73 | 0.639 | 1.231 | 0.517–2.933 | ||||||
| No | 93 | |||||||||||||||
| Adjuvant radiotherapy | ||||||||||||||||
| Yes | 3 | 0.998 | <0.001 | 0/inf | 0.996 | <0.001 | 0/inf | |||||||||
| No | 135 | |||||||||||||||
| Respiratory complications | ||||||||||||||||
| Yes | 31 | 0.402 | 1.450 | 0.609–3.456 | 0.814 | 1.106 | 0.478–2.56 | |||||||||
| No | 108 | |||||||||||||||
| Circulatory complications | ||||||||||||||||
| Yes | 20 | 0.064 | 2.394 | 0.950–6.03 | 0.004 | 3.105 | 1.43–6.743 | 0.019 | 2.721 | 1.177–6.290 | ||||||
| No | 119 | |||||||||||||||
| RLNP | ||||||||||||||||
| Yes | 20 | 0.312 | 1.604 | 0.642–4.007 | 0.219 | 1.695 | 0.731–3.927 | |||||||||
| No | 119 | |||||||||||||||
OS, overall survival; HR, hazard ratio; CI, confidence interval; DFS, disease-free survival; COPD, chronic obstructive pulmonary disease; FDG-PET, fluorodeoxyglucose-positron emission tomography; VATS, video-assisted thoracic surgery; Ad, adenocarcinoma; inf, infinity; RLNP, recurrent laryngeal nerve palsy.
Relationship between stations 4, 5, and 6 LN metastasis status and prognosis
| LN station | Mediastinoscopy (+), n=69 (%) | Mediastinoscopy (−), n=70 (%) | Total, n=139 (%) | OS | DFS | |
|---|---|---|---|---|---|---|
| P value | P value | |||||
| Station 4 metastasis | 3 (4.35) | 6 (8.57) | 9 (6.47) | 0.59 | 0.35 | |
| Station 5 metastasis | 3 (4.35) | 8 (11.43) | 11 (7.91) | 0.41 | <0.001 | |
| Station 6 metastasis | 4 (5.80) | 5 (7.14) | 9 (6.47) | 0.32 | 0.005 |
LN, lymph node; OS, overall survival; DFS, disease-free survival.
Relationship between confirmation of LN status at each station and prognosis
| LN station | Lymphadenectomy (−) | Metastasis (+)/cases | OS | DFS | |||||
|---|---|---|---|---|---|---|---|---|---|
| Total, (n=91) (%) | Confirmed | Unconfirmed | P value | Survival | P value | Survival | |||
| Station 4 | 33 (32.3) | 12 | 21 | 8/70 | 0.20 | 0.750 | 0.10 | 0.486 | |
| Station 5 | 12 (13.2) | 1 | 11 | 8/80 | 0.92 | 0.875 | <0.001 | 0.250 | |
| Station 6 | 17 (18.7) | 2 | 15 | 6/76 | 0.35 | 1.000 | 0.01 | 0.400 | |
LN, lymph node; OS, overall survival; DFS, disease-free survival.
Univariate and multivariate analyses of the association between various risk factors and recurrent laryngeal nerve palsy
| Variables | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|
| P value | OR | 95% CI | P value | OR | 95% CI | ||
| Age ≥75 years | 0.02 | 0.191 | 0.021–0.860 | 0.02 | 0.075 | 0.009–0.621 | |
| Clinical stage ≥II | 0.006 | 3.925 | 1.328–11.944 | 0.92 | 1.090 | 0.205–5.790 | |
| FDG-PET accumulation | 0.006 | 4.717 | 1.383–15.912 | 0.30 | 2.320 | 0.473–11.400 | |
| Open thoracotomy | 0.02 | 3.424 | 1.172–10.556 | 0.10 | 3.8200 | 0.776–18.800 | |
| Station 4 LN dissection | 0.04 | 3.587 | 0.845–13.586 | 0.03 | 7.340 | 1.260–42.800 | |
| Station 4 and/or 5 nodal metastases | 0.05 | 3.297 | 0.985–14.360 | 0.83 | 0.832 | 0.150–4.610 | |
OR, odds ratio; CI, confidence interval; FDG-PET, fluorodeoxyglucose-positron emission tomography; LN, lymph node.
Characteristics of patients with recurrent laryngeal nerve palsy (n=20)
| Characteristics | Values |
|---|---|
| Age (years) | |
| Range | 47–80 |
| Mean ± SD | 65.85±8.04 |
| Sex, n (%) | |
| Male | 14 (70.0) |
| Clinical stage, n (%) | |
| ≥II | 11 (55.0) |
| Approach, n (%) | |
| VATS | 9 (45.0) |
| Mediastinoscopy, n (%) | 11 (55.0) |
| Pathological N factor, n (%) | |
| N2 | 5 (25.0) |
| Prognosis, n (%) | |
| Improvement | 14 (70.0) |
| Time required for improvement (months) | |
| Range | 0–15 |
| Mean ± SD | 5.71±3.69 |
| Surgery for RLNP, n (%) | 3 (15.0) |
| RLNP-related complications, n (%) | |
| Aspiration pneumonia | 4 (20.0) |
| Atelectasis | 2 (10.0) |
| Sputum retention | 1 (5.0) |
SD, standard deviation; VATS, video-assisted thoracic surgery; RLNP, recurrent laryngeal nerve palsy.
Annual transition of surgical procedures and univariate analysis of the association between surgical procedures and recurrent laryngeal nerve palsy
| Surgical procedures† | Annual transition | Univariate analysis | |||||
|---|---|---|---|---|---|---|---|
| 2014–2016, n=27 (%) | 2017–2019, n=47 (%) | Total, n=74 (%) | P value | OR | 95% CI | ||
| Bot-com | 19 (70.4) | 42 (89.4) | 61 (82.4) | 0.68 | 2.060 | 0.241–98.474 | |
| Vce-com | 19 (70.4) | 43 (91.5) | 62 (83.8) | >0.99 | 1.855 | 0.214–89.181 | |
| Vpe-com | 26 (96.3) | 46 (97.9) | 72 (97.3) | >0.99 | Inf | 0.028–inf | |
| Rsu-com | 19 (70.4) | 43 (91.5) | 62 (83.8) | 0.66 | 0.744 | 0.120–8.206 | |
| Rde-com | 16 (59.3) | 39 (83.0) | 55 (74.3) | >0.99 | 1.328 | 0.230–14.118 | |
| EK-use | 0 (0.0) | 6 (12.8) | 6 (0.08) | 0.03 | 8.278 | 0.932–74.895 | |
| VSS-use | 12 (44.4) | 5 (10.6) | 17 (23.0) | 0.04 | 4.224 | 0.831–21.757 | |
| PA-tap | 18 (66.7) | 29 (61.7) | 47 (63.5) | 0.08 | 6.044 | 0.757–279.725 | |
| RLNP | 3 (11.1) | 9 (19.1) | 12 (16.2) | – | – | – | |
†, eight surgical procedures were evaluated: confirmation and dissection of the ligamentum Botalli (Bot-com), the vagal nerve traveling along the central (Vce-com) and peripheral (Vpe-com) sides of the recurrent laryngeal nerve bifurcation, and the shallow (Rsu-com) and deep (Rde-com) branches of the recurrent laryngeal nerve before the start of LN dissection, as well as conventional EK (EK-use) and VSS (VSS-use) use near the recurrent laryngeal nerve (distance approximately <3 mm) and PA taping (PA-tap) during LN dissection. inf, infinity; OR, odds ratio; CI, confidence interval; EK, electric knife; VSS, vessel sealing system; PA, pulmonary artery; RLNP, recurrent laryngeal nerve palsy; LN, lymph node.